A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

Application No: NA_00068294

Principal Investigator: Daniel Harrison

For more information please contact Julie Fiol at 410-955-8704

This research is being conducted to determine if natalizumab is effective in slowing disability progression in multiple sclerosis patients with secondary progression.  Natalizumab is a once monthly intravenous infusion that is currently FDA-approved for use in relapsing remitting MS. 

Participants must be between the ages of 18 and 58 and have a diagnosis of secondary progressive MS with evidence of disability progression for more than 2 years independent of relapses.  Participants will be randomized to receive once-monthly infusions of natalizumab or placebo.